Researchers Found An Almost 10-Times Increased Risk Of Severe Intestinal Malabsorption Associated With Benicar After 2-Years Use Compared To Some Other Blood Pressure Medications
SUMMARY: In May 2014 the medical journal Gastroenterology published an article, “Severe Malabsorption Associated With Olmesartan: A French Nationwide Cohort Study”, which provides some insight concerning the association between Benicar and a side effect that is often initially mistaken for celiac disease.
From the Abstract for this medical journal article about that French Benicar study:
Conclusion: [Benicar (olmesartan)] was associated with an increased risk of severe intestinal malabsorption. The increased risk appears after one year of treatment and reaches 9.53 after 2 years of [Benicar (olmesartan)]. ARBs other than [Benicar (olmesartan)] were not associated with an increased risk of severe intestinal malabsorption.
Our law firm is investigating these sprue-like enteropathy cases involving Benicar, Benicar HCT, Azor, and Tribenzor as possible products liability lawsuits against the responsible drug company, Daiichi Sankyo, Inc.[Read this article in full at original source]
Benicar / Benicar HCT / Azor / Tribenzor
Free Case Evaluation
Strictly Confidential, No Obligation.